CredoScientia - Bibliothèque

An Unconscionable Decision.

Thérapies de Conversion

Swartz, H. A. (2026). An Unconscionable Decision.. Am J Psychother, 79(2), 47-48. https://doi.org/10.1176/appi.psychotherapy.20260023

01/06/2026 Lire →

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

BACKGROUND: A significant portion of primary liver cancer patients in China are diagnosed at intermediate-to-advanced stages, often making them ineligible for curative surgery. Furthermore, high posto…

Thérapies de Conversion

Wang, Z., Sun, H., Zhou, J., Xie, Q., Bi, X., Liu, X., Liu, R., Zhao, M., Bai, X., Ji, Y., Xu, L., Jia, W., Zeng, S., Li, G., Zhang, W., Shen, S., Rao, S., Shi, G., Zhang, L., … Alliance, o. f. . L. i. v. e. r. . C. a. n. c. e. r. . C. o. n. v. e. r. s. i. o. n. . T. h. e. r. a. p. y. ,. . L. i. v. e. r. . C. a. n. c. e. r. . C. o. m. m. i. t. t. e. e. ,. . C. h. i. n. a. . A. n. t. i. -. C. a. n. c. e. r. . A. s. s. o. c. i. a. t. i. o. n. (2026). Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).. Hepatobiliary Surg Nutr, 15(3), 72. https://doi.org/10.21037/hbsn-2025-129

01/06/2026 Lire →

"Conversion Therapy" in the US-Progress, Missed Opportunities, and Future Directions.

Thérapies de Conversion

Gavulic, K. A., Pachankis, J. E., & Aaron, D. G. (2026). "Conversion Therapy" in the US-Progress, Missed Opportunities, and Future Directions.. JAMA Pediatr, 180(6), 599-600. https://doi.org/10.1001/jamapediatrics.2026.0394

01/06/2026 Lire →

Prognostic Value of Pathological Response After Conversion Therapy and Salvage Surgery in Unresectable Hepatocellular Carcinoma.

BACKGROUND AND AIMS: To evaluate the prognostic significance of pathological response in patients with initially unresectable hepatocellular carcinoma (uHCC) who underwent salvage resection after succ…

Thérapies de Conversion

Chi, Q. Y., Gao, X. D., Wang, M., Liu, Q. Y., Zeng, Y. Y., Yang, L. F., Liu, Z. J., Wang, S. J., Weng, S. G., & Zhang, Z. B. (2026). Prognostic Value of Pathological Response After Conversion Therapy and Salvage Surgery in Unresectable Hepatocellular Carcinoma.. Liver Int, 46(6), e70681. https://doi.org/10.1111/liv.70681

01/06/2026 Lire →

Conversion surgical after neoadjuvant immunochemotherapy achieves survival comparable to initially resectable disease in borderline resectable esophageal cancer.

BACKGROUND: Immune checkpoint inhibitors have demonstrated preliminary safety and efficacy in treating borderline resectable esophageal squamous cell carcinoma (BR-ESCC). We aimed to compare treatment…

Thérapies de Conversion

Xu, B., Wang, H., Zhang, C., Luo, T., Xiong, J., Ran, X., Liu, J., Shi, G., & Fu, M. (2026). Conversion surgical after neoadjuvant immunochemotherapy achieves survival comparable to initially resectable disease in borderline resectable esophageal cancer.. Int J Clin Oncol, 31(6), 1017-1025. https://doi.org/10.1007/s10147-026-03018-x

01/06/2026 Lire →

Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report.

BACKGROUND: Malignant hepatocellular neoplasm, not otherwise specified (HCN, NOS), is a rare primary liver tumor showing overlapping features of hepatoblastoma and hepatocellular carcinoma. Because of…

Thérapies de Conversion

Moriyama, E., Koga, H., Niizeki, T., Iwamoto, H., Shimose, S., Shirono, T., Tokushige, T., Nakano, M., Kuromatsu, R., Goto, T., Honda, M., Hibi, T., Mikami, Y., Kondo, R., Akiba, J., & Kawaguchi, T. (2026). Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report.. Hepatol Res, 56(6), 1047-1052. https://doi.org/10.1111/hepr.70142

01/06/2026 Lire →

Conversion therapy using transarterial chemoembolization plus tislelizumab for unresectable hepatocellular carcinoma: effects on tumor necrosis and anti-tumor immune response.

PURPOSE: We analyzed the clinical efficacy and safety of conversion therapy for unresectable hepatocellular carcinoma (uHCC) using transarterial chemoembolization (TACE) plus tislelizumab and characte…

Thérapies de Conversion

Yao, Q., Chen, G., Yu, Y., Chen, Z., An, X., Xie, X., Wang, Q., Chen, D., & Sun, H. (2026). Conversion therapy using transarterial chemoembolization plus tislelizumab for unresectable hepatocellular carcinoma: effects on tumor necrosis and anti-tumor immune response.. Clin Transl Oncol, 28(6), 2208-2218. https://doi.org/10.1007/s12094-025-04159-7

01/06/2026 Lire →

[Translational therapeutic strategies and timing of surgery for peritoneal metastasis in colorectal cancer].

Peritoneal metastasis from colorectal cancer is characterized by aggressive biological behavior, rapid disease progression, and poor overall prognosis, making it one of the most challenging conditions…

Thérapies de Conversion

Liu, L., Hu, Y. T., Kong, X. X., Zhu, A. K., Sun, L. F., & Wang, J. (2026). [Translational therapeutic strategies and timing of surgery for peritoneal metastasis in colorectal cancer].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 636-647. https://doi.org/10.3760/cma.j.cn441530-20260212-00087

25/05/2026 Lire →

[Conversion efficacy and safety analysis of PD-1 inhibitor combined with albumin-bound paclitaxel and SOX chemotherapy regimen in initially unresectable advanced gastric cancer].

To evaluate the efficacy and safety of a PD-1 inhibitor combined with albumin-bound paclitaxel and the SOX chemotherapy regimen for the conversion therapy of initially unresectable advanced gastric c…

Thérapies de Conversion

Tang, Y. F., Zhou, B. Q., Wen, B. B., Yu, K., Jia, J. J., Sha, Y., Liu, J. X., Li, L. Y., Xu, S. M., & Fan, R. F. (2026). [Conversion efficacy and safety analysis of PD-1 inhibitor combined with albumin-bound paclitaxel and SOX chemotherapy regimen in initially unresectable advanced gastric cancer].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 662-671. https://doi.org/10.3760/cma.j.cn441530-20250923-00354

25/05/2026 Lire →

[Surgical strategies following conversion therapy for metastatic colorectal cancer].

Curative resection following conversion therapy has become a key strategy for improving the prognosis of patients with advanced colorectal cancer (CRC). Based on the latest evidence from clinical stud…

Thérapies de Conversion

Cong, Z. Y., & Xu, Y. (2026). [Surgical strategies following conversion therapy for metastatic colorectal cancer].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 627-635. https://doi.org/10.3760/cma.j.cn441530-20260313-00118

25/05/2026 Lire →

[Efficacy of conversion therapy and prognostic factors in patients with synchronous gastric cancer liver metastasis].

To investigate the efficacy of conversion therapy and prognostic factors in patients with synchronous gastric cancer liver metastasis (GCLM), and to evaluate the clinical value of the Chinese Classif…

Thérapies de Conversion

Li, B., Deng, R., Liu, Y., Wang, X. J., Zhang, L., Wu, L. L., Tian, Y., Zheng, X. J., & Liang, H. (2026). [Efficacy of conversion therapy and prognostic factors in patients with synchronous gastric cancer liver metastasis].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 653-661. https://doi.org/10.3760/cma.j.cn441530-20260222-00092

25/05/2026 Lire →

[Precise prevention and treatment strategies for surgical complications after conversion therapy for gastric cancer].

Conversion therapy offers a potential curative opportunity for patients with initially unresectable gastric cancer. However, the consequent systemic and local pathophysiological changes significantly …

Thérapies de Conversion

Zhou, Y. B. (2026). [Precise prevention and treatment strategies for surgical complications after conversion therapy for gastric cancer].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 621-626. https://doi.org/10.3760/cma.j.cn441530-20260302-00105

25/05/2026 Lire →